Scythian Biosciences announces licensing agreement with Isodiol International

2 minute read
07 May 2018

On May 7, 2018, Scythian Biosciences Corp. (TSXV: SCYB) (Frankfurt: 9SB) (OTC – Nasdaq Intl: SCCYF) announced that it had signed a letter agreement with Isodiol International Inc. (CSE: ISOL) to import and distribute Isodiol products to certain countries in the Caribbean, Central America and South America, including Argentina, Colombia and Jamaica. The term of the agreement shall be for an initial period of five years, with the ability of the parties to extend the five year period upon mutually agreed upon terms. Scythian has also committed to invest $2 million into Isodiol, in exchange for units in Isodiol.

Isodiol is a market leader in pharmaceutical grade phytochemical compounds and an industry leader in the manufacturing and development of CBD consumer products

Scythian is a research and development company committed to advancing prevention and treatment efforts for concussion and traumatic brain injury with its proprietary cannabinoid-based combination drug therapy.

Peter Simeon and Josh Almario of Gowling WLG advised Scythian with respect to the negotiation of this agreement and investment.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.